** Shares of Australia's Sigma Healthcare set to more than double their annual gains in 2024
** Stock on track for a more than 160% rise in 2024 after a 70% gain in the previous year
** Stock has risen steadily over the year on optimism surrounding its $5.78 bln backdoor merger with private pharmacy chain Chemist Warehouse
** SIG in November received clearance from the competition watchdog to go ahead with the deal
** Chemist Warehouse in late 2023 said it would buy SIG for stock and A$700 million ($435.47 million) in cash, giving it a roughly 85% stake in the merged entity and a backdoor to list on the stock exchange
** After the deal got green light, Jefferies analysts said the merged company will give investors access to an excellent retail franchise
** Investment research firm Morningstar said it views the deal as strategically sound and transformational for Sigma, as it creates Australia's largest pharmacy chain backed by significant distribution infrastructure
** Morningstar also forecast the newly formed group to increase its underlying EBIT by around 13% on average over next five years
($1 = 1.6075 Australian dollars)
<^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ Sigma Healthcare
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^>
(Reporting by Rishav Chatterjee in Bengaluru)
((Rishav.Chatterjee@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。